Rationale: During pneumonia, pathogen-host interaction evokes inflammation and lung barrier dysfunction. Tie2 activation by angiopoietin-1 reduces, whereas Tie2 blockade by angiopoietin-2 increases, inflammation and permeability during sepsis. The role of angiopoietin-1/-2 in pneumonia remains unidentified.
Community-acquired pneumonia (CAP) is a significant cause of morbidity and mortality worldwide, and Streptococcus pneumoniae is the most prevalent causal pathogen identified in CAP (1, 2) . Despite effective antibiotic therapy, pathogen-host interaction in pneumonia may evoke pulmonary endothelial permeability leading to protein exudation and edema formation, and finally to life-threatening lung failure (3) .
Pneumonia-induced pulmonary hyperpermeability can be attributed to both direct effects of pathogenic factors and an uncontrolled host response. Among host factors, recruitment of polymorphonuclear neutrophils, increased release of proinflammatory cytokines and other, partly unidentified factors may contribute to the pathogenesis (3) . The angiopoietins (Ang-1 through Ang-4) are ligands for the receptor tyrosine kinase Tie2 (4) . Ang-1 and Ang-2 are well-known contributors to angiogenesis (5) and regulators of inflammation and vascular leakage (6) (7) (8) . Angiopoietin-1 is constitutively expressed in pericytes, vascular smooth muscle cells, and fibroblasts (9) . Constitutively released Ang-1 activates Tie2, resulting in reduction of NF-kB translocation, vascular cell adhesion molecule-1 presentation, Rho-kinase inhibition, and activation of Rac1, phosphatidylinositol 3-kinase/Akt, and Kruppel-like factor-2, among others (5, (10) (11) (12) . Consequently, inflammation and apoptosis are reduced and endothelial barrier function is stabilized (8, 11, 13) . In contrast, Ang-2 augments inflammation and permeability by acting as an Ang-1 antagonist at Tie2 (6, 14) .
In the systemic circulation, Ang-2 is produced and stored in endothelial cells (15) . Exogenous inflammatory stimuli induce rapid Ang-2 release (9), and Ang-2 enhances properties of specific proinflammatory mediators including tumor necrosis factor (TNF)-a (6) . Further, direct impairment of endothelial integrity by Ang-2 has been suggested (7) . In patients with sepsis, Ang-2 serum levels were higher than in healthy volunteers and even further increased in patients with sepsis-associated lung injury (7) . Previous studies support usage of Ang-2 as a biomarker for risk evaluation in sepsis and acute respiratory distress syndrome (ARDS) (16) (17) (18) (19) . However, little is known about the expression and function of Ang-1 and Ang-2 in the pulmonary circulation, and the role of Ang-1 and Ang-2 in pneumonia has not been investigated so far. We hypothesized that Ang-2 is increased and contributes to lung injury in pneumonia, whereas endogenous Ang-1 is decreased and exogenous Ang-1 improves lung barrier function in severe pneumococcal pneumonia.
To comprehensively investigate the role of Ang-1 and Ang-2 in pneumonia, we accompanied human clinical studies with in vitro cell culture studies and in vivo mouse experiments (1) . Ang-1 and Ang-2 were quantified in the serum of patients with CAP in two different independent and prospectively collected cohorts, and the predictive value of Ang-2 regarding mortality, intensive care unit (ICU) admission, and length of hospital stay was analyzed (2) . Expression and regulation of Ang-1 and Ang-2 were analyzed in human postmortem sampled lung tissue from patients who died of pneumonia and in murine lungs with pneumonia (3) . Endothelial regulation of Ang-2 on stimulation with the pneumococcal exotoxin pneumolysin and its impact on endothelial permeability were analyzed in human and murine cells in vitro, as well as ex vivo in isolated perfused and ventilated mouse lungs (4) . Therapeutic application of Ang-1 was performed in mice with severe pneumococcal pneumonia. 
ORIGINAL ARTICLE
Some of the results presented here have been previously reported in the form of abstracts (20, 21) .
Methods
For a detailed description, see the online supplement.
Clinical Study
This was an ancillary study of CAPNETZ (Community-acquired Pneumonia Competence Network [22, 23] ) and PROGRESS (Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Sepsis [24] ), both being observational, prospective studies enrolling consecutive patients with CAP as approved by central and local ethics committees (see the online supplement).
Data and laboratory samples were obtained as controls from healthy volunteers, as approved by the local ethics committee. Written informed consent was obtained from each patient and volunteer, or from each patient's legal representative.
The first cohort comprised CAPNETZ patients not surviving the first 28 days after pneumonia diagnosis; they were matched with CAPNETZ survivors at a 1:1 ratio based on age, sex, and CRB-65 (confusion, respiratory rate, blood pressure 65 yr of age and older) score (0-3). Samples were taken within 24 hours of diagnosis. As second cohort, PROGRESS provided samples of consecutive patients with CAP enrolled within 48 hours of hospitalization (Day 0) and monitored for 3 days thereafter (Days 1-3).
Serum Ang-1 and Ang-2 levels were quantified with a Quantikine ELISA kit (R&D Systems).
Human Postmortem Immunohistochemistry
Lungs with and without histologically diagnosed acute pneumonia were examined. All patients had given informed consent at admission. Immunohistochemical staining is detailed in the online supplement.
Endothelial Cell Experiments
Human pulmonary microvascular endothelial cells (ECs) (PromoCell), human umbilical vein ECs (25) , and murine lung ECs were grown to confluence on evaporated gold microelectrodes connected to an electrical cell-substrate impedancesensing system (Applied Biophysics) (26) to continuously monitor transcellular electrical resistance (TER). Cells were treated with pneumolysin (PLY) (27) or Ang-2 (R&D Systems). Further, cells pretreated with Ang-1 (R&D Systems) or solvent for 30 minutes were exposed to PLY. Ang-2 was determined in supernatants 3 hours after PLY stimulation.
Angiopoietin-2 Knockdown
On four consecutive days, mice were intravenously treated with liposomal siRNA (AtuPLEX; Silence Therapeutics AG) against Ang-2 mRNA, to establish suppression of endothelial gene expression (28) . Lungs were isolated, perfused, and ventilated 24 hours thereafter, human serum albumin (HSA) admixed to perfusate, PLY infused, and HSA measured in BAL fluid (BALF) (29) .
Angiopoietin-1 Therapy in Murine Pneumonia
Animal procedures were approved by institutional and governmental (LAGeSo Berlin) authorities. Mice were anesthetized with ketamine/xylazine and transnasally inoculated with 5 3 10 6 cfu of S. pneumoniae (NCTC 7978) (29) . Body weight and rectal temperature were measured. Lungs were quick-frozen for qRT-PCR 12, 24, 36, and 48 hours after infection (28) . Mice received Ang-1 or Increased angiopoietin (Ang)-2 and reduced Ang-1 serum levels in human pneumonia, with highest Ang-2 levels in patients with community-acquired pneumonia (CAP) not surviving the first 28 days after pneumonia diagnosis. In the first patient cohort (CAPNETZ), admission levels of (A) Ang-2 and (B) Ang-1 were quantified in the serum of patients with CAP (CRB-65 score, 0-3; n = 148; 50% nonsurvivors [28 d ; n = 74] matched with survivors at a 1:1 ratio based on age, sex, and CRB-65 score) and in healthy control subjects (n = 24), and (C) the Ang-2/Ang-1 ratio was calculated. Data are presented as box plots depicting median, quartiles, and range excluding outliers (circles). *P , 0.05, ***P , 0.001, ****P , 0.0001. CAPNETZ = Community-acquired Pneumonia Competence Network; CRB-65 = confusion, respiratory rate, blood pressure, 65 years of age and older.
solvent intravenously 22, 34, and 46 hours after infection. Pulmonary arterial flushing and BAL were performed 48 hours after infection, leukocytes were differentiated by fluorescence-activated cell sorting (FACSCalibur; BD Biosciences), and cytokines were quantified (Bio-Rad). To determine permeability, HSA was infused intravenously 47 hours after infection, and the BALF-to-serum ratio was calculated 48 hours after infection (29) .
Statistical Analyses
Patient data analysis is detailed in the online supplement. Experimental data are expressed as means 1 SEM. Comparisons were performed using Mann-Whitney U tests followed by Bonferroni-Holm corrections where appropriate. For comparison of time points in the second patient cohort, pairwise t tests were performed and a linear mixed model was used for global tests. Correlation analyses were performed using Spearman correlation coefficients. P values less than 0.05 were considered significant. Analyses were performed with GraphPad Prism 6.05 (GraphPad Software).
Results

Ang-1 and Ang-2 Levels in Serum of Patients with CAP
The first study cohort (CAPNETZ) comprised 74 patients who did not survive the first 28 days after CAP diagnosis, and matched 74 survivors. The median length of hospital stay (LOS) of the survivors was 11 days (Table 1) . Characteristics of patients and volunteers of the CAPNETZ study cohort are summarized in Table E1 in the online supplement. In the serum of these patients with CAP (survivors and nonsurvivors), increased Ang-2 (4. Table 1 ).
In the CAPNETZ study cohort, patients with CAP were older than healthy volunteers (Table E1) ; however, serum levels of Ang-1 and Ang-2 in patients with CAP did not correlate with age (Table E2) .
To further evaluate the association between Ang-2 serum levels and clinical outcome, a second study cohort (PROGRESS) was included that comprised 395 hospitalized patients with CAP, with showed higher Ang-2 serum levels at all investigated time points compared with survivors (light gray boxplots; n = 376). Data are represented as box plots depicting median, quartiles, and range excluding outliers (circles). *P , 0.05, **P , 0.01. (B) Receiver operating characteristic curves for serum Ang-2, CURB-65, and serum procalcitonin (PCT) at admission (Day 0) alone and in combination in predicting hard endpoint (HEP; n = 395). HEP was defined as death by any cause within 28 days of enrollment or specific treatment on an intensive care ward. As specific treatment, the following were considered: substantial respiratory support (ventilation, extracorporeal oxygenation, oxygen supplementation of at least 6 L/min, except for patients who were already receiving ventilation at home), treatment with catecholamines, or dialysis (except for patients with chronic kidney failure). The combination of Ang-2 and CURB-65 had the best predictive power. The area under the curve for the combination of Ang-2 and CURB-65 was significantly higher than that for CURB-65 alone (P = 0.0021), PCT alone (P = 0.0015), and the combination of both (P = 0.035). CURB-65 = confusion, urea nitrogen, respiratory rate, blood pressure, 65 years of age and older; PROGRESS = Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Sepsis.
ORIGINAL ARTICLE
4.8% dying within 28 days of study enrollment. The median LOS of the survivors was 8 days ( Definition of abbreviations: Ang-2 = angiopoietin-2; AUC = area under the curve; CI = confidence interval; CURB-65 = confusion, urea nitrogen, respiratory rate, blood pressure, 65 years of age and older; PCT = procalcitonin. Hard endpoint was defined as death by any cause within 28 days of enrollment or specific treatment on an intensive care ward. As specific treatment, the following were considered: substantial respiratory support (ventilation, extracorporeal oxygenation, oxygen supplementation of at least 6 L/min, except for patients who were already receiving ventilation at home), treatment with catecholamines, or dialysis (except for patients with chronic kidney failure). Definition of abbreviations: Ang-2 = angiopoietin-2; AUC = area under the curve; CI = confidence interval; CURB-65 = confusion, urea nitrogen, respiratory rate, blood pressure, 65 years of age and older; LOS = length of hospital stay; PCT = procalcitonin. For patients who died within 7 or 14 days, LOS was set to more than 7 days or more than 14 days, respectively, for this type of analysis.
and LOS . 14 (P = 0.0001). For all endpoints, the combination of all three parameters is not significantly better than Ang-2 and CURB-65. Tables 3 and  4 show detailed AUC values, and ROCs for predicting the hard endpoint are displayed in Figure 2B . Correlation analysis of Ang-2 serum levels and clinical and laboratory outcome parameters on Day 0 in the PROGRESS patient cohort revealed several correlations. The strongest correlations were observed for oxygenation index (r = 20.37), bilirubin (r = 0.28), creatinine (r = 0.35), PCT (r = 0.43), and C-reactive protein (r = 0.41) values (all P , 0.0001) in serum.
Human Postmortem Immunohistochemistry
Examination of human postmortem lung tissue revealed a distinct pattern of expression of Ang-1, Ang-2, and their receptor Tie2 in the lung tissue of patients with pneumonia. Ang-1 protein expression was found across the lung parenchyma in various cell types including endothelial and epithelial cells, smooth muscle cells of arteries and bronchi, macrophages, and polymorphonuclear neutrophils. In contrast, Ang-2 and Tie2 proteins exclusively localized in pulmonary blood vessels, pointing toward their expression in endothelial cells (Figure 3) . A trend toward reduced Ang-1 and Tie2, and increased Ang-2 protein expression in postmortem lung tissue from patients with pneumonia as compared with control subjects was observed; however, semiquantitative morphologic analysis of staining intensity did not reach significance.
Endothelial Cell Experiments
To investigate in greater detail the possible contribution of Ang-2 to pneumonia pathophysiology, Ang-2 release from cultured endothelial cells was analyzed on stimulation with PLY. Confluent human umbilical vein endothelial cell (HUVEC) monolayers stimulated for 3 hours with recombinant PLY dose-dependently liberated Ang-2 ( Figure 4A ). Further, Ang-2 impaired endothelial barrier integrity in HUVEC ( Figure 4B ) and human pulmonary microvascular endothelial cell (hPMVEC) monolayers ( Figure  4C ) reversibly, and in murine lung EC monolayers in part reversibly ( Figure 4D ).
Angiopoietin-2 Contributed to Pneumolysin-evoked Lung Injury in Mouse Lungs
To analyze the contribution of Ang-2 in PLY-induced lung barrier destabilization at a whole-organ level, isolated perfused and ventilated mouse lungs were employed. In this model, RNA interference-mediated suppression of Ang-2 mRNA expression (siRNA ) in the pulmonary endothelium resulted in reduced PLY-evoked permeability in comparison with control-treated lungs (luciferase-specific siRNA, siRNA Luc ; Figure 4E ). A 50% reduction of pulmonary Ang-2 mRNA expression was achieved after intravenous administration of siRNA lipoplexes ( Figure E1 ).
Angiopoietin-1 Reduced Lung Barrier Failure
We evaluated whether Ang-1 was able to reduce pneumonia-related barrier failure. PLY stimulation evoked a dose-dependent decrease in TER of HUVEC monolayers, displaying loss of endothelial integrity ( Figure 5A ). Incubation of confluent HUVEC and hPMVEC monolayers with Ang-1 attenuated the PLY-induced TER decrease compared with solvent ( Figures 5B  and 5C ). . Pneumolysin evoked angiopoietin (Ang)-2 liberation, and Ang-2 contributed to endothelial barrier dysfunction. (A) Human umbilical vein endothelial cells (HUVECs) were exposed to increasing concentrations of pneumolysin (PLY) for 3 hours and Ang-2 was quantified in supernatants (blank, n = 7; solvent, n = 5; PLY, n = 4). (B-D) Transendothelial electrical resistance (TER) of endothelial cell monolayers was monitored. HUVECs (n = 5), human pulmonary microvascular endothelial cells (hPMVECs; n = 5), or primary murine lung endothelial cells (mLECs; n = 3) were exposed to Ang-2 (2 mg/ml). (E) In mice, siRNA specific for Ang-2 or luciferase (Luc, as control) was injected intravenously once daily on four consecutive days (n = 6). Twenty-four hours after the last administration, lungs were isolated, perfused, and ventilated and exposed to PLY (1 mg/ml). In the control group (n = 4), neither siRNA molecules nor PLY was applied. Values are given as (A and E) means 1 SEM or (B-D) means; *P , 0.05 versus solvent group (A) or between indicated groups (E). HSA = human serum albumin.
Further, pulmonary regulation of Ang-1 and Ang-2 was investigated in pneumonia in vivo. Mice infected with S. pneumoniae showed decreased body weight and temperature ( Figures 6A and 6B ) as signs of disease over time. After infection, pulmonary mRNA expression of Ang-1 was decreased after 24 hours and at later time points ( Figure 6C ). Pulmonary Ang-2 mRNA was increased by trend compared with control mice 24, 36, and 48 hours after infection ( Figure 6D) .
Given the protective effect of Ang-1 in vitro and the regulation of Ang-1 and Ang-2 in vivo, the therapeutic potential of Ang-1 in vivo was investigated. Ang-1 therapy of established severe pneumonia partly prevented the decrease in body weight and temperature observed in solvent-treated mice (Figures 7A and 7B) . Lung hyperpermeability was significantly reduced by Ang-1 as revealed by calculation of the HSA BALF-to-plasma ratio ( Figure 7C ). Moreover, neutrophil recruitment ( Figure 7D ) and inflammatory cytokines ( Figure 7E ) in BALF were efficiently reduced by Ang-1 in pneumonic mice.
Discussion
Current management of severe pneumonia could be improved by predictive severity scores and adjunctive therapies. In the present study, we performed a holistic analysis of the role of angiopoietins in pneumonia by combining clinical data with comprehensive in vivo and in vitro pathomechanistic experiments. We demonstrated that specific angiopoietins are useful biomarkers to predict pneumonia outcome and potential therapeutic targets in addition to antibiotics to prevent acute lung failure.
The CRB-65 and CURB-65 scores are recommended in international guidelines (30) , and CRB-65 is widely used as a predictor of death in patients with newly diagnosed pneumonia (23, 31) . Both scores are comparable for mortality prediction (23, 30, 32) . However, these scores alone provide insufficient power to predict 30-day mortality or ICU admission (32) (33) (34) . Addition of specific biomarkers may possibly improve the accuracy of CURB-65/CRB-65. The use of Ang-2 for risk evaluation in sepsis, sepsis-induced ARDS, and other critical illness has been controversially discussed (7, (16) (17) (18) (19) (35) (36) (37) ). An NHLBI ARDS Network study reported that plasma Ang-2 levels measured in 931 subjects with acute lung injury did not have prognostic value for mortality in the subgroup of infection-related ALI (n = 653) (35) . Calfee and colleagues compared plasma biomarkers between two studies, a single-center and a multicenter study, and observed that Ang-2 was lower in the plasma of patients with direct ARDS compared with patients with indirect ARDS (due to nonpulmonary sepsis) (38) . In contrast to the present work, the ARDS Network studies did not analyze pneumonia patients without ARDS.
The presented analysis revealed decreased serum Ang-1 levels and increased Ang-2 levels in patients with pneumonia as compared with healthy control subjects. Further, we observed that Ang-2 serum levels significantly differed between survivors and nonsurvivors. Moreover, Ang-2 serum levels were negatively correlated with the oxygenation index and positively correlated with various laboratory outcome parameters such as PCT, bilirubin, creatinine, and C-reactive protein. We therefore tested for an additive prognostic value of Ang-2 serum levels in patients with pneumonia. Because of our limited sample size, we decided not to build a new score from scratch but to analyze possible improvements of the established CURB-65 score including Ang-2. Indeed, ROC analysis revealed significantly improved prognostic accuracy of CURB-65 for 28-day mortality, our predefined composite "hard endpoint," and length of hospital stay if combined with Ang-2 serum levels. Accordingly, the implied prognostic improvement achieved by adding the Ang-2 value to CURB-65 is not restricted to mortality prediction but also helps identify patients who require more than standard monitoring and treatment (39) . At this stage, adding Ang-2 to the pneumonia severity index would be of interest, but not all necessary parameters were available. It would also be interesting to investigate whether changes in Ang-2 serum levels are of particular importance in specific types of pneumonia, but for this analysis by far more samples from patients with defined pneumonia etiology are necessary. To enhance the rationale for a possible prognostic and pathogenic role of angiopoietins in pneumonia, particularly in pneumonia-induced endothelial disruption and pulmonary hyperpermeability, we investigated the pulmonary localization, regulation, and function of Ang-1 and Ang-2 in pneumonia. Consistent with histological studies of other tissues (4, 40) , Ang-2 and Tie2 in human lungs were found to be expressed exclusively in lung blood vessels, pointing toward expression in endothelial cells, whereas Ang-1 was expressed in various cell types. Although Ang-2 protein in human serum as well as Ang-2 mRNA in mouse lungs increased in pneumonia, semiquantitative analysis of human postmortem lung tissue did not reveal significantly increased Ang-2 protein expression in pneumonia, which may partly result from 1) emptied endothelial Ang-2 stores in pneumonia, 2) postmortem reduction in tissue quality, and 3) limited precision of histologic quantification. Of note, we found increased Ang-2 release in human endothelial cells on stimulation with pneumolysin, an important exotoxin of S. pneumoniae and central contributor to lung hyperpermeability in pneumococcal pneumonia (29, 41) . Previous studies demonstrated Ang-2 mRNA upregulation after stimulation with proinflammatory mediators, LPS, or hyperoxia in endothelial cells (9, 42, 43) , where Ang-2 is stored in Weibel-Palade bodies (WPB) and rapidly released on stimulation with WPB secretagogues including thrombin, phorbol 12-myristate 13-acetate, TNF-a, and thapsigargin (15) . Also, PLY is known to stimulate IL-8 and von Willebrand factor exocytosis of WPBs in pulmonary endothelial cells (44) . Furthermore, Ang-2 disrupts endothelial architecture (15) . Accordingly, in the current electrical cell impedance-sensing experiments Ang-2 decreased the monolayer integrity of various types of endothelial cells, including hPMVECs, reversibly. The complex mechanisms of pneumolysin-induced permeability in intact lungs are incompletely understood and may include cellular pore formation and inflammation (29, 45, 46) . Hypothesizing that Ang-2 might be involved in pneumolysin-induced hyperpermeability, we applied RNA interference in vivo by treating mice intravenously with liposomal, stabilized Ang-2 siRNA before stimulating their isolated perfused and ventilated lungs with pneumolysin. Lungs of mice treated with Ang-2-specific siRNA showed reduced permeability on pneumolysin stimulation compared with lungs of mice treated with control siRNA, suggesting that Ang-2 contributed to pneumolysin-induced lung permeability. An increase in Ang-2 mRNA expression in mouse lungs after LPS stimulation has been reported (9) . In the lungs of S. pneumoniae-infected mice we also observed a time-dependent increase in Ang-2 mRNA expression, while Ang-1 expression decreased. Body weight and temperature decrease reflected disease progression. Figure 7 . Angiopoietin (Ang)-1 treatment prevented lung injury in mice with severe pneumococcal pneumonia. Mice were transnasally infected with Streptococcus pneumoniae (S. pn.), and 22, 34, and 46 hours after infection Ang-1 (50 mg/kg) or solvent was injected intravenously. Forty-eight hours after infection, (A) body weight and (B) body temperature were measured, (C) the human serum albumin (HSA) BAL fluid (BALF)-to-plasma ratio was measured to determine microvascular leakage, and (D) BALF leukocytes and (E) cytokines were analyzed. Values are given as means 1 SEM; n = 5 (shaminfected groups); n = 10-12 (S. pn.-infected groups). *P , 0.05, **P , 0.01 between the indicated groups. G-CSF = granulocyte colony-stimulating factor; KC = keratinocyte chemoattractant; LYM = lymphocytes; MAC = macrophages; MIP-2 = macrophage inflammatory protein-2; n.d. = not detectable; PMN = polymorphonuclear neutrophils; RANTES = regulated upon activation, normal T cell expressed and secreted; TNF-a = tumor necrosis factor-a.
Hashimoto and Pittet suggested that the ratio between Ang-1 and Ang-2 is more important for determining endothelial integrity than the absolute Ang-2 concentration, with a decreased Ang-2/ Ang-1 ratio stabilizing endothelial barrier function (47) . Indeed, preventive adenoviral Ang-1 gene transfer or administration of mesenchymal stem cells overexpressing Ang-1 as well as prophylactic application of recombinant Ang-1 protein diminished pulmonary hyperpermeability induced by subsequent LPS injection in mice (11, 48, 49) . However, therapeutic use of Ang-1 in pneumonia has not been examined so far. Thus, we first investigated whether Ang-1 protein application is able to reduce pneumolysin-evoked endothelial barrier disruption in vitro. Indeed, Ang-1 diminished pneumolysin-induced injury of HUVEC and hPMVEC monolayers. We then treated mice with recombinant Ang-1 protein in an intervening instead of prophylactic setting. Ang-1 treatment of S. pneumoniae-infected mice started 22 hours after infection, when severe pneumonia was already established. Subsequently, we observed reduction of lung permeability, pulmonary leukocyte recruitment, and inflammatory cytokine secretion, and clinical outcome was clearly improved in Ang-1-treated as compared with untreated mice. The exact contributions of Ang-1-dependent antiinflammatory effects on the one hand and direct barrier-stabilizing properties of Ang-1 on the other hand could not be deciphered in the current in vivo treatment experiment. Antiinflammatory effects of Ang-1 have been described previously in murine lung injury (49) , as well as in vascular endothelial growth factor-stimulated HUVECs and human umbilical artery ECs in vitro (13) . Moreover, direct stabilizing effects of Ang-1 on endothelial cells were observed in the current as well as in various previous studies in vitro where cells were stimulated with N,N-dimethylsphingosine (50) or the serum of sepsis patients with high Ang-2 levels (7).
In summary, we found that pneumonia is associated with decreased Ang-1 and increased Ang-2 serum levels in humans. Further, Ang-2 serum levels were even more increased in nonsurvivors compared with survivors. Prognostic accuracy of CURB-65 for 28-day survival, need for ICU treatment, and length of hospital stay exceeding 7 or 14 days was improved by adding Ang-2 serum levels. These results suggest that Ang-2 may add prognostic value to existing or future pneumonia severity scores. In complementary experimental studies, pneumolysin evoked Ang-2 liberation, and Ang-2 contributed to pneumolysininduced pulmonary hyperpermeability. Therapeutic treatment with Ang-1 reduced inflammation and permeability in murine pneumococcal pneumonia, thereby protecting mice from the development of acute lung injury. Thus, interventional reduction of the Ang-2/Ang-1 ratio may provide a therapeutic perspective for pneumonia-induced acute lung failure. n Author disclosures are available with the text of this article at www.atsjournals.org.
